Therapeutic Approach

Archive: July, 2019

Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings

Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28 LOS ANGELES(July 31, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to […]

Leave Your Comments »

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES (July 11, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that it […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES (July 2, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed their final visit in the Company’s first […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD